Extab and Sopharma Release: Tabex Shown to be a Highly Cost Effective Treatment for Smoking Cessation

Published: Jan 09, 2012

WILMINGTON, Del. & LONDON--(BUSINESS WIRE)--Extab Corporation (“Extab”) a clinical stage biopharmaceutical company with a focus on smoking cessation, today announced the results of a cost effectiveness study published in the peer reviewed journal, Nicotine and Tobacco Research. These data are based on the results of the Tabex Smoking Cessation (“TASC”) 740-patient pivotal trial, which were published in the New England Journal of Medicine on September 29, 2011.

Back to news